(VIANEWS) – Simulations Plus (SLP), MFA Financial (MFA), Physicians Realty Trust (DOC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Simulations Plus (SLP)
38.9% sales growth and 5.51% return on equity
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.
Earnings Per Share
As for profitability, Simulations Plus has a trailing twelve months EPS of $0.48.
PE Ratio
Simulations Plus has a trailing twelve months price to earnings ratio of 73.04. Meaning, the purchaser of the share is investing $73.04 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.51%.
2. MFA Financial (MFA)
37.5% sales growth and 5.14% return on equity
MFA Financial, Inc., together with its subsidiaries, operates as a real estate investment trust in the United States. The company invests in residential mortgage assets, including non-agency mortgage-backed securities, agency MBS, and credit risk transfer securities; residential whole loans, including purchased performing loans, purchased credit deteriorated, and non-performing loans; and mortgage servicing rights related assets. MFA Financial, Inc. was incorporated in 1997 and is based in New York, New York.
Earnings Per Share
As for profitability, MFA Financial has a trailing twelve months EPS of $0.63.
PE Ratio
MFA Financial has a trailing twelve months price to earnings ratio of 19.21. Meaning, the purchaser of the share is investing $19.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.14%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 28, 2024, the estimated forward annual dividend rate is 1.4 and the estimated forward annual dividend yield is 11.61%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 499.9%, now sitting on 260.84M for the twelve trailing months.
3. Physicians Realty Trust (DOC)
24.6% sales growth and 3.72% return on equity
Physicians Realty Trust is a self-managed healthcare real estate company organized to acquire, selectively develop, own and manage healthcare properties that are leased to physicians, hospitals and healthcare delivery systems. The Company invests in real estate that is integral to providing high quality healthcare. The Company conducts its business through an UPREIT structure in which its properties are owned by Physicians Realty L.P., a Delaware limited partnership (the “operating partnership”), directly or through limited partnerships, limited liability companies or other subsidiaries. The Company is the sole general partner of the operating partnership and, as of September 30, 2020, owned approximately 97.4% of OP Units.
Earnings Per Share
As for profitability, Physicians Realty Trust has a trailing twelve months EPS of $0.48.
PE Ratio
Physicians Realty Trust has a trailing twelve months price to earnings ratio of 46.79. Meaning, the purchaser of the share is investing $46.79 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.72%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 5, 2024, the estimated forward annual dividend rate is 1.2 and the estimated forward annual dividend yield is 5.34%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 27.5%, now sitting on 2.41B for the twelve trailing months.
4. Banco Latinoamericano de Comercio Exterior, S.A. (BLX)
22.7% sales growth and 16.19% return on equity
Banco Latinoamericano de Comercio Exterior, S.A., a multinational bank, primarily engages in the financing of foreign trade in Latin America and the Caribbean. The company operates through two segments, Commercial and Treasury. It offers short and medium-term bilateral, structured and syndicated credits, and loan commitments; financial guarantee contracts, such as issued and confirmed letters of credit, and stand-by letters of credit; and guarantees covering commercial risk and other assets, as well as co-financing arrangements, underwriting of syndicated credit facilities, structured trade financing in the form of factoring and vendor financing, and financial leasing. The company also provides treasury solutions, which include term deposits and private placements. It primarily serves financial institutions, corporations, and sovereigns and state-owned entities. The company was formerly known as Banco Latinoamericano de Exportaciones, S.A. and changed its name to Banco Latinoamericano de Comercio Exterior, S.A. in June 2009. Banco Latinoamericano de Comercio Exterior, S.A. was founded in 1977 and is headquartered in Panama City, the Republic of Panama.
Earnings Per Share
As for profitability, Banco Latinoamericano de Comercio Exterior, S.A. has a trailing twelve months EPS of $5.28.
PE Ratio
Banco Latinoamericano de Comercio Exterior, S.A. has a trailing twelve months price to earnings ratio of 5.74. Meaning, the purchaser of the share is investing $5.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.19%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 5, 2024, the estimated forward annual dividend rate is 2 and the estimated forward annual dividend yield is 6.6%.
Yearly Top and Bottom Value
Banco Latinoamericano de Comercio Exterior, S.A.’s stock is valued at $30.29 at 16:22 EST, way under its 52-week high of $34.45 and way above its 52-week low of $20.02.
Revenue Growth
Year-on-year quarterly revenue growth grew by 29.7%, now sitting on 271.04M for the twelve trailing months.
5. FormFactor (FORM)
18.5% sales growth and 13.62% return on equity
FormFactor, Inc. designs, manufactures, and sells probe cards, analytical probes, probe stations, metrology systems, thermal systems, and cryogenic systems to semiconductor companies and scientific institutions. It operates in two segments, Probe Cards and Systems. The company offers probe cards to test various semiconductor device types, including systems on a chip products, mobile application processors, microprocessors, microcontrollers, and graphic processors, as well as radio frequency, analog, mixed signal, image sensor, electro-optical, dynamic random access memory, NAND flash memory, and NOR flash memory devices, as well as computer processor devices; and analytical probes, which are used for a range of applications, including device characterization, electrical simulation model development, failure analysis, and prototype design debugging for universities, research institutions, semiconductor integrated device manufacturers, semiconductor foundries, and fabless semiconductor companies. It also provides probe systems for semiconductor design engineers to capture and analyze accurate data; surface metrology systems for the development, production, and quality control of semiconductor products; thermal subsystems, such as thermal chucks and other test systems used in probe stations and other applications; and precision cryogenic instruments, semiconductor tests, and measurement systems. In addition, the company offers on-site probe card maintenance and service training, seminars, and telephone support services. It markets and sells its products through direct sales force, manufacturers' representatives, and distributors in the United States, Taiwan, South Korea, China, Europe, Japan, Malaysia, Singapore, and internationally. The company was incorporated in 1993 and is headquartered in Livermore, California.
Earnings Per Share
As for profitability, FormFactor has a trailing twelve months EPS of $1.54.
PE Ratio
FormFactor has a trailing twelve months price to earnings ratio of 31.67. Meaning, the purchaser of the share is investing $31.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.62%.
Moving Average
FormFactor’s worth is under its 50-day moving average of $53.42 and higher than its 200-day moving average of $46.95.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 40.9% and 70%, respectively.
Volume
Today’s last reported volume for FormFactor is 1031720 which is 48.99% above its average volume of 692471.
6. Molina Healthcare (MOH)
11.7% sales growth and 25.12% return on equity
Molina Healthcare, Inc. provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments, Medicaid, Medicare, Marketplace, and Other. The company served in across 19 states. The company was founded in 1980 and is headquartered in Long Beach, California.
Earnings Per Share
As for profitability, Molina Healthcare has a trailing twelve months EPS of $18.23.
PE Ratio
Molina Healthcare has a trailing twelve months price to earnings ratio of 19.05. Meaning, the purchaser of the share is investing $19.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.12%.
Volume
Today’s last reported volume for Molina Healthcare is 362442 which is 44.46% below its average volume of 652582.
7. CONMED Corporation (CNMD)
5.6% sales growth and 11.86% return on equity
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Earnings Per Share
As for profitability, CONMED Corporation has a trailing twelve months EPS of $3.14.
PE Ratio
CONMED Corporation has a trailing twelve months price to earnings ratio of 23.32. Meaning, the purchaser of the share is investing $23.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.86%.
Sales Growth
CONMED Corporation’s sales growth is 4.6% for the current quarter and 5.6% for the next.
